It's another excellent performance on the gross margin level. That has to imply taking costs out. There's a continuous process of trying to squeeze costs. |
Shire has more to lose than Barr has to gain. |
This could be anything from a relatively trivial delay to more clinical trials. We'll need to learn more before we can be unequivocal on the impact. |